Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

Key Points

• HC Wainwright lowered Journey Medical’s Q3 2026 EPS estimate to $0.01 from $0.03, citing weaker expectations; it also reduced estimates for later years through 2030.
• Journey Medical’s latest quarter modestly beat expectations, reporting a $0.01-per-share loss versus the projected $0.02 loss and revenue of $18.51 million versus $18.36 million expected.
• Shares opened at $6.65, while analyst sentiment remained mixed: B. Riley raised its price target to $15, but the overall consensus rating was “Hold” with an average target of $14.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - HC Wainwright decreased their Q3 2026 earnings estimates for shares of Journey Medical in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.03. The consensus estimate for Journey Medical's current full-year earnings is $0.17 per share. HC Wainwright also issued estimates for Journey Medical's Q4 2026 earnings at $0.02 EPS, FY2027 earnings at $1.07 EPS, FY2028 earnings at $1.66 EPS, FY2029 earnings at $1.81 EPS and FY2030 earnings at $1.92 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The firm had revenue of $18.51 million during the quarter, compared to the consensus estimate of $18.36 million. Journey Medical had a negative net margin of 8.95% and a negative return on equity of 20.67%.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded Journey Medical from a "hold" rating to a "buy" rating in a report on Saturday, June 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Journey Medical in a research report on Friday, July 17th. Finally, B. Riley Financial reiterated a "buy" rating and set a $15.00 price objective (up from $12.00) on shares of Journey Medical in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Journey Medical currently has a consensus rating of "Hold" and an average price target of $14.00.

Journey Medical Trading Up 3.4%

Shares of NASDAQ DERM opened at $6.65 on Friday. Journey Medical has a 1-year low of $4.31 and a 1-year high of $9.56. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.72 and a quick ratio of 1.47. The business's 50 day moving average is $6.59 and its two-hundred day moving average is $6.61. The stock has a market capitalization of $183.07 million, a P/E ratio of -30.23 and a beta of 1.08.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors and hedge funds have recently modified their holdings of DERM. Wasatch Advisors LP increased its stake in Journey Medical by 34.0% in the second quarter. Wasatch Advisors LP now owns 2,858,930 shares of the company's stock worth $20,241,000 after purchasing an additional 725,560 shares during the period. Opaleye Management Inc. increased its stake in Journey Medical by 0.4% in the 4th quarter. Opaleye Management Inc. now owns 975,000 shares of the company's stock worth $7,517,000 after buying an additional 3,936 shares during the period. J. Goldman & Co LP bought a new stake in Journey Medical during the 4th quarter valued at about $6,155,000. Vanguard Group Inc. boosted its position in Journey Medical by 8.9% in the 3rd quarter. Vanguard Group Inc. now owns 615,229 shares of the company's stock valued at $4,380,000 after buying an additional 50,241 shares during the period. Finally, Pale Fire Capital SE grew its stake in Journey Medical by 8.4% in the 1st quarter. Pale Fire Capital SE now owns 481,987 shares of the company's stock worth $2,261,000 after acquiring an additional 37,345 shares in the last quarter. 7.25% of the stock is owned by institutional investors.

Key Headlines Impacting Journey Medical

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Journey Medical reported a loss of $0.01 per share versus the $0.02 consensus loss, while revenue of $18.51 million topped estimates of $18.36 million. The earnings beat suggests better-than-expected operating performance. Journey Medical Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Emrosi momentum remained strong: Management highlighted a 20% sequential increase for Emrosi, which reached $8.1 million, along with 38% high-quality coverage. The company also signaled continued average selling price gains in the second half of 2026, supporting the growth outlook. Journey Medical Signals Continued ASP Gains
• Positive Sentiment: B. Riley raised its price target: The firm reaffirmed a “buy” rating and increased its target to $15 from $12, implying substantial potential upside from the stock’s recent $6.65 level. This reinforces the bullish view that Emrosi and the company’s dermatology portfolio can drive future growth.
• Neutral Sentiment: Long-term profitability remains a key catalyst: HC Wainwright still projects positive EPS from 2027 onward, including $1.07 in 2027 and $1.66 in 2028, but the estimates are now below its prior forecasts. Investors will likely focus on whether improving product sales can translate into sustained profitability.
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: Q3 2026 EPS was reduced to $0.01 from $0.03 and Q4 to $0.02 from $0.07. Estimates for fiscal 2027 through 2030 were also lowered, including 2030 EPS to $1.92 from $1.98. The cuts indicate expectations for slower near-term earnings growth and are the primary bearish factor in the news flow.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source